\-\ Texto\\:\\ \ \(0\)\
\-\ ft4\\:\\ 2\\.10\\ \\ \\(0\\.71\\-1\\.85\\ ng\\/dl\\)\ \(0\)\
\-\ tsh\\:\\ \\<0\\.08\\ \\(0\\.49\\-4\\.67\\ mciu\\/ml\\)\ \(0\)\
\-\ thyroid\\ stimulating\\ antibody\\:\\ \\ 226\\ \\ \\(0\\-129\\%\\ baseline\\)\ \(0\)\
\-\ i131\\ uptake\\:\\ \\ 4\\ hours\\ \\ 23\\%\\ \\(2\\-12\\%\\)\\,and\\ 24\\ hours\\ 59\\%\\ \\(12\\-30\\%\\)\ \(0\)\
\-\ 15\\ mci\\ of\\ i131\\ was\\ orally\\ administered\\ for\\ graves\\'\\ disease\\ therapy\\.\ \(0\)\
\-\ tc\\ 99m\\ pertechnetate\\ scan\\ demonstrates\\ an\\ increase\\ in\\ overall\\ radiotracer\\ accumulation\\ compared\\ to\\ background\\.\\ a\\ pyramidal\\ lobe\\ is\\ clearly\\ evident\\.\\ a\\ slight\\ nodular\\ appearance\\ is\\ visualized\\,\\ but\\ no\\ heterogeneity\\ or\\ photopenic\\-appearing\\ nodules\\ are\\ seen\\ to\\ suggest\\ a\\ toxic\\ multi\\-nodular\\ goiter\\.\\ however\\,\\ ideally\\,\\ imaging\\ with\\ radioactive\\ iodine\\ should\\ be\\ performed\\ to\\ exclude\\ the\\ possibility\\ of\\ \\"discordant\\ nodule\\(s\\)\\"\ \(0\)\
\-\ graves\\'\\ disease\\ with\\ an\\ underlying\\ multinodular\\ goiter\\ is\\ most\\ likely\ \(0\)\
\-\ graves\\'\\ disease\ \(0\)\
\-\ toxic\\ multinodular\\ goiter\ \(1\)\
\-\ marine\\-lehnhart\\ syndrome\ \(0\)\
\-\ 30\\ year\\ old\\ female\\ with\\ symptoms\\ of\\ thyrotoxicosis\ \(1\)\
\-\ see\\ factoid\ \(116\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ goiter\\:\\ 0\\.30517909111296615\ \(0\)\
\-\ graves\\:\\ 0\\.29922424565843864\ \(0\)\
\-\ i131\\:\\ 0\\.24537588769343735\ \(0\)\
\-\ multinodular\\:\\ 0\\.22146791987268977\ \(0\)\
\-\ toxic\\:\\ 0\\.18480943957850657\ \(0\)\
\-\ nodular\\:\\ 0\\.1440833186949137\ \(0\)\
\-\ hours\\:\\ 0\\.13789643014786201\ \(0\)\
\-\ ideally\\:\\ 0\\.133680488563584\ \(0\)\
\-\ discordant\\:\\ 0\\.13014167958491943\ \(0\)\
\-\ 226\\:\\ 0\\.12480560348048447\ \(0\)\
\-\ orally\\:\\ 0\\.12480560348048447\ \(0\)\
\-\ 30\\:\\ 0\\.1234269169133424\ \(0\)\
\-\ pyramidal\\:\\ 0\\.11763762123450637\ \(0\)\
\-\ stimulating\\:\\ 0\\.116257717399852\ \(0\)\
\-\ disease\\:\\ 0\\.1139218252735091\ \(0\)\
\-\ heterogeneity\\:\\ 0\\.1127189084211874\ \(0\)\
\-\ thyrotoxicosis\\:\\ 0\\.1127189084211874\ \(0\)\
\-\ pertechnetate\\:\\ 0\\.11169539912985334\ \(0\)\
\-\ radioactive\\:\\ 0\\.10897004485178348\ \(0\)\
\-\ ft4\\:\\ 0\\.10526517268298664\ \(0\)\
\-\ antibody\\:\\ 0\\.10339726450611862\ \(0\)\
\-\ mci\\:\\ 0\\.10339726450611862\ \(0\)\
\-\ background\\:\\ 0\\.10172636370432205\ \(0\)\
\-\ iodine\\:\\ 0\\.09974141521947955\ \(0\)\
\-\ baseline\\:\\ 0\\.09565253180077568\ \(0\)\
\-\ administered\\:\\ 0\\.09362523645565879\ \(0\)\
\-\ tsh\\:\\ 0\\.08740788420834847\ \(0\)\
\-\ tc\\:\\ 0\\.08740788420834847\ \(0\)\
\-\ accumulation\\:\\ 0\\.08740788420834847\ \(0\)\
\-\ exclude\\:\\ 0\\.08740788420834847\ \(0\)\
\-\ 99m\\:\\ 0\\.08677764671767613\ \(0\)\
\-\ 59\\:\\ 0\\.08577990329675353\ \(0\)\
\-\ clearly\\:\\ 0\\.0852100615239496\ \(0\)\
\-\ possibility\\:\\ 0\\.08412835440675392\ \(0\)\
\-\ overall\\:\\ 0\\.08311574095215887\ \(0\)\
\-\ slight\\:\\ 0\\.079221264085527\ \(0\)\
\-\ radiotracer\\:\\ 0\\.07896751643615509\ \(0\)\
\-\ evident\\:\\ 0\\.07775632578574886\ \(0\)\
\-\ 23\\:\\ 0\\.07459512725958849\ \(0\)\
\-\ is\\:\\ 0\\.07432326391414663\ \(0\)\
\-\ underlying\\:\\ 0\\.0738486887940955\ \(0\)\
\-\ suggest\\:\\ 0\\.0734882439660514\ \(0\)\
\-\ compared\\:\\ 0\\.07313580968988859\ \(0\)\
\-\ increase\\:\\ 0\\.07262142222771588\ \(0\)\
\-\ nodules\\:\\ 0\\.07187983253767564\ \(0\)\
\-\ nodule\\:\\ 0\\.07140403015786265\ \(0\)\
\-\ thyroid\\:\\ 0\\.07109457858838308\ \(0\)\
\-\ visualized\\:\\ 0\\.07064143662501363\ \(0\)\
\-\ uptake\\:\\ 0\\.06956218425432077\ \(0\)\
\-\ an\\:\\ 0\\.06918693092981508\ \(0\)\
\-\ to\\:\\ 0\\.06784812497593859\ \(0\)\
\-\ 24\\:\\ 0\\.06413692952829662\ \(0\)\
\-\ factoid\\:\\ 0\\.06317839675644935\ \(0\)\
\-\ 15\\:\\ 0\\.06113065151842819\ \(0\)\
\-\ should\\:\\ 0\\.05902832683162657\ \(0\)\
\-\ see\\:\\ 0\\.056274735458287865\ \(0\)\
\-\ appearance\\:\\ 0\\.05453776836619153\ \(0\)\
\-\ syndrome\\:\\ 0\\.05453776836619153\ \(0\)\
\-\ likely\\:\\ 0\\.05405957465822194\ \(0\)\
\-\ scan\\:\\ 0\\.05367180742465105\ \(0\)\
\-\ however\\:\\ 0\\.0535446304018861\ \(0\)\
\-\ performed\\:\\ 0\\.05351931692524312\ \(0\)\
\-\ with\\:\\ 0\\.053142461940040964\ \(0\)\
\-\ of\\:\\ 0\\.05311072829254176\ \(0\)\
\-\ lobe\\:\\ 0\\.052279139895344114\ \(0\)\
\-\ therapy\\:\\ 0\\.051977939363590776\ \(0\)\
\-\ symptoms\\:\\ 0\\.049497256388223276\ \(0\)\
\-\ imaging\\:\\ 0\\.04754235463199964\ \(0\)\
\-\ most\\:\\ 0\\.047080661623673754\ \(0\)\
\-\ demonstrates\\:\\ 0\\.045448570700717554\ \(0\)\
\-\ but\\:\\ 0\\.044735023255795175\ \(0\)\
\-\ female\\:\\ 0\\.04365347587681346\ \(0\)\
\-\ seen\\:\\ 0\\.04259013182022097\ \(0\)\
\-\ be\\:\\ 0\\.036697984186652474\ \(0\)\
\-\ are\\:\\ 0\\.03432730666859092\ \(0\)\
\-\ was\\:\\ 0\\.03152790543053584\ \(0\)\
\-\ or\\:\\ 0\\.03147112000772095\ \(0\)\
\-\ no\\:\\ 0\\.029418148766859227\ \(0\)\
\-\ year\\:\\ 0\\.027879494124358018\ \(0\)\
\-\ for\\:\\ 0\\.027419210061711143\ \(0\)\
\-\ old\\:\\ 0\\.026773965085772823\ \(0\)\
\-\ in\\:\\ 0\\.02250472554844177\ \(0\)\
\-\ and\\:\\ 0\\.018693459364602604\ \(0\)\
\-\ the\\:\\ 0\\.01805102101328959\ \(0\)\
